Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy

An investigation in 24,831 patients

Frederick Wolfe, Kaleb D Michaud, Theodore Pincus

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Objective. Fatigue is a common and distressing symptom in patients with rheumatoid arthritis (RA) and other rheumatic diseases. Reports have suggested profound improvements in fatigue after onset of anti-tumor necrosis factor-α (anti-TNF) therapy. In addition, physician and patient groups now identify fatigue as a very important symptom. However, data to support these observations are lacking. We evaluate the importance of fatigue in relation to other measures of clinical status, describe predictors of fatigue, and investigate fatigue levels in patients treated with anti-TNF therapy. Methods. A total of 852 patients participated in a symptom-importance preference study. Additional analyses of fatigue and other clinical status variables were performed in up to 21,016 patients with RA and 3815 patients with osteoarthritis (OA) participating in the National Data Bank for Rheumatic Diseases. Results. In ranking studies of the relative importance of fatigue compared with function, pain, cognition, gastrointestinal symptoms, and sleep, 8.0% of patients ranked fatigue as the most important variable, compared with 32.1% for function and 21.5% for pain. Multivariable studies of clinical change over 6 months found that changes in fatigue were weakly associated with changes in health status, in contradistinction to results for pain, function, and depression. Fatigue levels and fatigue predictors were similar in RA and OA patients. RA patients treated with anti-TNF therapy did not have lower fatigue scores compared with those not treated with this type of therapy. Conclusion. Among RA patient self-report measures, fatigue is not ranked as important as functional disability, pain, or depression by most patients. This relative ranking is confirmed by examination of clinical improvement data. Fatigue levels and predictors of fatigue are essentially the same in RA and OA. Although anti-TNF therapy lowers fatigue levels, there is no evidence that this effect is greater for anti-TNF therapy than for other RA treatments.

Original languageEnglish (US)
Pages (from-to)2115-2120
Number of pages6
JournalJournal of Rheumatology
Volume31
Issue number11
StatePublished - Nov 1 2004

Fingerprint

Fatigue
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Therapeutics
Osteoarthritis
Pain
Rheumatic Diseases
Depression
Self Report
Cognition
Health Status
Sleep

Keywords

  • Anti-tumor necrosis factor therapy
  • Fatigue
  • Osteoarthritis
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy : An investigation in 24,831 patients. / Wolfe, Frederick; Michaud, Kaleb D; Pincus, Theodore.

In: Journal of Rheumatology, Vol. 31, No. 11, 01.11.2004, p. 2115-2120.

Research output: Contribution to journalArticle

@article{4d398bc58d204afb8b5837bd87780014,
title = "Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: An investigation in 24,831 patients",
abstract = "Objective. Fatigue is a common and distressing symptom in patients with rheumatoid arthritis (RA) and other rheumatic diseases. Reports have suggested profound improvements in fatigue after onset of anti-tumor necrosis factor-α (anti-TNF) therapy. In addition, physician and patient groups now identify fatigue as a very important symptom. However, data to support these observations are lacking. We evaluate the importance of fatigue in relation to other measures of clinical status, describe predictors of fatigue, and investigate fatigue levels in patients treated with anti-TNF therapy. Methods. A total of 852 patients participated in a symptom-importance preference study. Additional analyses of fatigue and other clinical status variables were performed in up to 21,016 patients with RA and 3815 patients with osteoarthritis (OA) participating in the National Data Bank for Rheumatic Diseases. Results. In ranking studies of the relative importance of fatigue compared with function, pain, cognition, gastrointestinal symptoms, and sleep, 8.0{\%} of patients ranked fatigue as the most important variable, compared with 32.1{\%} for function and 21.5{\%} for pain. Multivariable studies of clinical change over 6 months found that changes in fatigue were weakly associated with changes in health status, in contradistinction to results for pain, function, and depression. Fatigue levels and fatigue predictors were similar in RA and OA patients. RA patients treated with anti-TNF therapy did not have lower fatigue scores compared with those not treated with this type of therapy. Conclusion. Among RA patient self-report measures, fatigue is not ranked as important as functional disability, pain, or depression by most patients. This relative ranking is confirmed by examination of clinical improvement data. Fatigue levels and predictors of fatigue are essentially the same in RA and OA. Although anti-TNF therapy lowers fatigue levels, there is no evidence that this effect is greater for anti-TNF therapy than for other RA treatments.",
keywords = "Anti-tumor necrosis factor therapy, Fatigue, Osteoarthritis, Rheumatoid arthritis",
author = "Frederick Wolfe and Michaud, {Kaleb D} and Theodore Pincus",
year = "2004",
month = "11",
day = "1",
language = "English (US)",
volume = "31",
pages = "2115--2120",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "11",

}

TY - JOUR

T1 - Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy

T2 - An investigation in 24,831 patients

AU - Wolfe, Frederick

AU - Michaud, Kaleb D

AU - Pincus, Theodore

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Objective. Fatigue is a common and distressing symptom in patients with rheumatoid arthritis (RA) and other rheumatic diseases. Reports have suggested profound improvements in fatigue after onset of anti-tumor necrosis factor-α (anti-TNF) therapy. In addition, physician and patient groups now identify fatigue as a very important symptom. However, data to support these observations are lacking. We evaluate the importance of fatigue in relation to other measures of clinical status, describe predictors of fatigue, and investigate fatigue levels in patients treated with anti-TNF therapy. Methods. A total of 852 patients participated in a symptom-importance preference study. Additional analyses of fatigue and other clinical status variables were performed in up to 21,016 patients with RA and 3815 patients with osteoarthritis (OA) participating in the National Data Bank for Rheumatic Diseases. Results. In ranking studies of the relative importance of fatigue compared with function, pain, cognition, gastrointestinal symptoms, and sleep, 8.0% of patients ranked fatigue as the most important variable, compared with 32.1% for function and 21.5% for pain. Multivariable studies of clinical change over 6 months found that changes in fatigue were weakly associated with changes in health status, in contradistinction to results for pain, function, and depression. Fatigue levels and fatigue predictors were similar in RA and OA patients. RA patients treated with anti-TNF therapy did not have lower fatigue scores compared with those not treated with this type of therapy. Conclusion. Among RA patient self-report measures, fatigue is not ranked as important as functional disability, pain, or depression by most patients. This relative ranking is confirmed by examination of clinical improvement data. Fatigue levels and predictors of fatigue are essentially the same in RA and OA. Although anti-TNF therapy lowers fatigue levels, there is no evidence that this effect is greater for anti-TNF therapy than for other RA treatments.

AB - Objective. Fatigue is a common and distressing symptom in patients with rheumatoid arthritis (RA) and other rheumatic diseases. Reports have suggested profound improvements in fatigue after onset of anti-tumor necrosis factor-α (anti-TNF) therapy. In addition, physician and patient groups now identify fatigue as a very important symptom. However, data to support these observations are lacking. We evaluate the importance of fatigue in relation to other measures of clinical status, describe predictors of fatigue, and investigate fatigue levels in patients treated with anti-TNF therapy. Methods. A total of 852 patients participated in a symptom-importance preference study. Additional analyses of fatigue and other clinical status variables were performed in up to 21,016 patients with RA and 3815 patients with osteoarthritis (OA) participating in the National Data Bank for Rheumatic Diseases. Results. In ranking studies of the relative importance of fatigue compared with function, pain, cognition, gastrointestinal symptoms, and sleep, 8.0% of patients ranked fatigue as the most important variable, compared with 32.1% for function and 21.5% for pain. Multivariable studies of clinical change over 6 months found that changes in fatigue were weakly associated with changes in health status, in contradistinction to results for pain, function, and depression. Fatigue levels and fatigue predictors were similar in RA and OA patients. RA patients treated with anti-TNF therapy did not have lower fatigue scores compared with those not treated with this type of therapy. Conclusion. Among RA patient self-report measures, fatigue is not ranked as important as functional disability, pain, or depression by most patients. This relative ranking is confirmed by examination of clinical improvement data. Fatigue levels and predictors of fatigue are essentially the same in RA and OA. Although anti-TNF therapy lowers fatigue levels, there is no evidence that this effect is greater for anti-TNF therapy than for other RA treatments.

KW - Anti-tumor necrosis factor therapy

KW - Fatigue

KW - Osteoarthritis

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=7544227525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7544227525&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 2115

EP - 2120

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 11

ER -